1 December 2015 - Eisai Co., Ltd. announced today that the U.S. FDA has accepted for review a New Drug Application for a once-daily formulation of its anti-obesity agent Belviq (lorcaserin hydrochloride) which has the potential to offer patients the convenience of once-daily treatment.

For more details, go to: http://www.eisai.com/news/news201582.html